ColoSense is designed for adults aged 45 to 85 years who are considered at average risk for colorectal cancer.
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the nationwide availability of ColoSense®, the only RNA-based at-home test for colorectal ...
Laboratory Corporation of America Holdings or LabCorp LH continues to remain in the headlines with major back-to-back developments within the company’s business. Following last week’s announcement of ...